Cabozantinib plus Atezolizumab Combination Trial Initiated for Advanced, Progressive Endocrine System Neoplasms
Background
Advanced and progressive endocrine tumors are often characterized by high vascularity and overexpression of various growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), insulin-like growth factor 1 (IGF-1), and transforming growth factor (TGF)-α and -β. The elevated expression of these factors is frequently associated with poor prognosis and can contribute to resistance to existing antiangiogenic therapies. There is a critical need for novel therapeutic strategies that can overcome these resistance mechanisms and improve outcomes for patients with these challenging malignancies.
Study Design
The CABATEN study is a multicohort phase II clinical trial designed to assess the efficacy of cabozantinib plus atezolizumab in advanced and progressive endocrine system tumors. Patients with refractory endocrine tumors will be enrolled and allocated into six distinct cohorts based on tumor origin, including thyroid, lung, pancreas, digestive tract, adrenal gland, and paraganglia. The primary objective is to determine the radiological objective response rate (ORR) using RECIST v1.1 criteria. Secondary endpoints include Progression-Free Survival (PFS), evaluating the time from treatment initiation to tumor progression or death.
Results
This document describes the protocol for the CABATEN study, a phase II clinical trial. As such, no efficacy or safety results are available yet from this ongoing investigation. The trial aims to evaluate the objective response rate (ORR) as its primary endpoint, which will be assessed following RECIST v1.1 criteria upon study completion. Secondary endpoints, including Progression-Free Survival (PFS), will also be analyzed. Data collection and analysis are currently underway, and the findings from this multicohort study will be reported in future publications once the trial has concluded and the results have been thoroughly evaluated. The study is designed to provide initial insights into the potential activity of this combination therapy.
Key Findings
- Trial protocol initiated for cabozantinib + atezolizumab in advanced endocrine tumors.
- Primary endpoint: radiological objective response rate (ORR) by
RECIST v1.1. - Secondary endpoint: Progression-Free Survival (PFS).
- Study targets highly vascular endocrine tumors expressing
VEGF,PDGF,IGF-1,TGF-α/β.
Why It Matters
If successful, the cabozantinib and atezolizumab combination could offer a novel therapeutic approach for patients with advanced and refractory endocrine system tumors, particularly those who have developed resistance to prior antiangiogenic treatments. This trial explores a dual-targeting strategy by inhibiting VEGF-mediated angiogenesis with cabozantinib and blocking the PD-L1 immune checkpoint with atezolizumab, potentially overcoming current treatment limitations. This trial aims to establish a new therapeutic option for a challenging cancer population, providing a foundation for future larger-scale studies and potentially changing the standard of care for these difficult-to-treat malignancies.
cabozantinib
atezolizumab
endocrine tumors
cancer
phase 2
clinical trial